Allergan Counterclaims Stand In $600M Botox Royalty Row
A California federal judge refused Tuesday to dismiss patent-related counterclaims Allergan Inc. filed after Miotox LLC alleged it owed $600 million for breaching a royalty deal over patents for Botox used...To view the full article, register now.
Already a subscriber? Click here to view full article